single Ig and TIR domain containingGenealiases: IL-1R8 · TIR8
Q-omics provides the consensus-scored SIGIRR profile across patient tissues and cancer cell-line models. SIGIRR expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, SIGIRR is differentially expressed in 9, with the highest sampling consensus in KIRC. Additionally, SIGIRR protein abundance shows 22,769 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight HNSC, KIRC, and LUAD as cancer lineages where SIGIRR shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SIGIRR — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SIGIRR survival associations across molecular data types. SIGIRR RNA expression shows survival associations in the most cancer types (26), followed by mutation status (2) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SIGIRR RNA expression–survival associations across cancer types. High SIGIRR expression shows unfavorable associations in LUSC and ACC, but favorable associations in HNSC, BLCA, CHOL and BRCA. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for SIGIRR RNA expression.
This table summarizes SIGIRR tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for SIGIRR. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SIGIRR shows lower tumor expression in KIRC, KIRP, LUSC and KICH and higher tumor expression in STAD and BRCA. The KIRC box plot shows higher SIGIRR RNA expression in normal versus tumor tissue (log2 FC = −1.089, t-test p < 0.001).
This table shows molecular features associated with SIGIRR in patient tissues and cancer cell lines. In patient samples, SIGIRR shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set. In cancer cell lines, SIGIRR RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Leukemia.
